1 / 3

PRODIGY

PRODIGY. Objective Assess the efficacy and safety of prolonged dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after coronary stenting, compared with currently recommended DAPT regimens Study Design Open-label, three-center, randomized, factorial assignment

bibiana
Download Presentation

PRODIGY

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. PRODIGY Objective • Assess the efficacy and safety of prolonged dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after coronary stenting, compared with currently recommended DAPT regimens Study Design • Open-label, three-center, randomized, factorial assignment • 1970 patients (all comers) who were scheduled for elective, urgent, or emergency coronary angioplasties were initially randomized 1:1:1:1 to one of four stent types: everolimus-eluting stent, paclitaxel-eluting stent, zotarolimus-eluting stent, or third-generation thin-strut BMS • At 30 days, patients in each group were further randomized to 6 or 24 months of DAPT Primary Composite Endpoint • Death, myocardial infarction (MI), or stroke, occurring from 31 days up to 24 months after intervention

  2. PRODIGY Primary Safety Outcome • BARC type 2, 3, and 5 bleeding Results • The cumulative risk of the primary outcome at 2 years was 10.1% with the 24-month treatment and 10.0% with the 6-month treatment • The individual risks of death, MI, CVA, or stent thrombosis did not differ between the two groups • Patients who received long-term DAPT had a roughly 2-fold greater risk of BARC bleeding events • The risks of TIMI-defined major bleeding and red blood cell transfusion were increased in the 24-month clopidogrel group • In patients who received first- or second-generation DES, outcomes failed to show a benefit of DAPT treatment for 24 months

  3. PRODIGY Conclusions • Although a smaller-than-previously anticipated benefit may exist, the increased bleeding, transfusions, and net adverse clinical events suggest that current recommendations may have overemphasized the benefit over the risk of long-term treatment with aspirin and clopidogrel • These findings question the validity of current guideline recommendations • If the risk of morbidity due to bleeding outweighs the anticipated benefit afforded by thienopyridine therapy, earlier discontinuation should be considered

More Related